Skip to search formSkip to main contentSkip to account menu

nelotanserin

Known as: 1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
G protein-coupled receptors (GPCRs), also known as 7-transmembrane receptors, are the single largest class of drug targets… 
2018
2018
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These… 
2018
2018
  • H. Mucke
  • Assay and drug development technologies
  • 2018
  • Corpus ID: 51679430
Review
2017
Review
2017
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available… 
Review
2017
Review
2017
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the… 
Review
2017
Review
2017
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations… 
2016
2016
Several agents are known to improve sleep induction and/or maintenance in patients with insomnia disorder. These include the… 
Review
2011
Review
2011
  • J. Monti
  • Sleep medicine reviews
  • 2011
  • Corpus ID: 29773003
2010
2010
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily… 
2010
2010
5-Hydroxytryptamine (5-HT)2A receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance…